Zobrazeno 1 - 10
of 20
pro vyhledávání: '"Takafumi Majima"'
Autor:
Shigeo Kono, Akihiro Himeno, Taiichiro Okajima, Yasuhisa Kato, Rika Araki, Kazuhiko Kotani, Mariko Oishi, Akira Sugawara, Noriko Satoh-Asahara, Masakazu Hattori, Takafumi Majima, Akira Shimatsu, Kazunori Koyama, Makito Tanabe, Takayoshi Suganami, Yoshihiro Ogawa
Publikováno v:
Clinical Journal of the American Society of Nephrology. 6:265-273
Obesity and metabolic syndrome (MS) increase the risk of cardiovascular disease (CVD), chronic kidney disease (CKD), and all-cause mortality. Serum cystatin C (S-CysC), a marker of GFR, has been shown to be associated with CVD and CKD. This study was
Autor:
Noriko Satoh, Takafumi Majima, Kazuhiko Kotani, Akira Shimatsu, Kazunori Yamada, Akihiro Himeno, Yoshihiro Ogawa, Takayoshi Suganami
Publikováno v:
Hypertension Research. 32:1004-1008
A recent clinical trial revealed that highly purified eicosapentaenoic acid (EPA), an n-3 polyunsaturated fatty acid, reduces the incidence of cardiovascular diseases. However, the detailed mechanism underlying the anti-atherogenic effect of EPA is s
Autor:
Tadashi Matsumura, Kiyoshi Ninomiya, Akira Shimatsu, Noriko Satoh, Atsushi Fukao, Takafumi Majima, Kazuwa Nakao, Yasato Komatsu
Publikováno v:
Journal of Bone and Mineral Metabolism. 27:168-174
Although osteoporosis in men is already a major public health problem, there is still a dearth of data about the effects of risedronate in male osteoporosis, especially in Japanese with primary osteoporosis. Therefore, the objective of our study was
Autor:
Kazuwa Nakao, Yasato Komatsu, Kiyoshi Ninomiya, Atsushi Fukao, Noriko Satoh, Tadashi Matsumura, Takafumi Majima, Akira Shimatsu
Publikováno v:
Endocrine Journal. 55:127-134
Because both raloxifene (RLX) and alfacalcidol (ALF) have been established as therapeutic agents for osteoporosis, it is tempting to speculate that the combination therapy of RLX and ALF might provide benefits over that of either one alone. However,
Autor:
Akira Shimatsu, Noriko Satoh, Takafumi Majima, Tadashi Matsumura, Atsushi Fukao, Kazuwa Nakao, Kiyoshi Ninomiya, Yasato Komatsu
Publikováno v:
Internal Medicine. 47:717-723
Objective Although osteoporosis in men previously was relatively neglected, bisphosphonates have been strongly suggested as potent therapeutic agents. However, there are few studies on the effects of risedronate in male osteoporosis, especially in Ja
Autor:
Kazuwa Nakao, Takeshi Morimoto, Takafumi Majima, Atsushi Fukao, Kentaro Doi, Chieko Takagi, Yasato Komatsu, Jerry Corners, Michika Shigemoto
Publikováno v:
Journal of Bone and Mineral Metabolism. 24:105-113
It has been well established that hyperthyroidism leads to diminished bone mineral density (BMD), and that a previous history of hyperthyroidism remains a risk factor for fractures. However, little is known about how to manage the reduction in BMD ca
Autor:
Kazuwa Nakao, Kentaro Doi, Michika Shigemoto, Takafumi Majima, Atsushi Fukao, Chieko Takagi, Yasato Komatsu, Jerry Corners
Publikováno v:
Endocrine Journal. 53:325-330
It is well known that pioglitazone, a potent thiazolidinedione, improves metabolic control. However, weight gain or peripheral edema may be of major clinical concern when using this agent. The purpose of our study was to prospectively evaluate the ef
Autor:
Jerry Corners, Michika Shigemoto, Ryohei Kato, Takafumi Majima, Chieko Takagi, Naomi Mizuta, Yasato Komatsu, Atsushi Fukao, Hiroshi Itoh, Kentaro Doi, Kazuwa Nakao
Publikováno v:
Endocrine Journal. 52:309-316
A 59-year-old woman with papillary thyroid carcinoma inside of an autonomously functioning thyroid nodule is described in this report. The patient was referred to our clinic because of rapid weight loss and swelling on the left side of the neck. Ultr
Autor:
Takafumi Majima, Kazuwa Nakao, T. Yamada, I. Hatanaka, Y. Koike, Michika Shigemoto, Yasato Komatsu, C. Takagi
Publikováno v:
Osteoporosis International. 16:907-913
The purpose of this study is to assess the association between type 2 diabetes and bone mineral density. This study included 145 Japanese patients (64 men and 81 women) with type 2 diabetes and 95 non-diabetic control subjects (41 men and 54 women) o
Publikováno v:
Nihon Naika Gakkai Zasshi. 93:2197-2200
症例は73歳女性.心不全の原因となった心房細動にコハク酸シベンゾリンを使用した際,低血糖が出現した.シベンゾリンによる低血糖の機序としてはATP感受性K+チャネル閉鎖によるインスリ